Stomach cancer laboratory findings

Stomach cancer Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Stomach Cancer from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic study of choice

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Endoscopy and Biopsy

Chest X Ray

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Stomach cancer laboratory findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Stomach cancer laboratory findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Stomach cancer laboratory findings

CDC on Stomach cancer laboratory findings

Stomach cancer laboratory findings in the news

Blogs on Stomach cancer laboratory findings

Directions to Hospitals Treating Stomach cancer

Risk calculators and risk factors for Stomach cancer laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:  Mohammed Abdelwahed M.D[2]

## Overview

[edit | edit source]

Laboratory findings in gastric cancer include anemia of chronic disease on complete blood count, liver function tests may reveal abnormalities in liver function tests, antigens such as carcinoembryonic antigen, glycoprotein CA 125, carbohydrate antigen 19-9, cancer antigen 72-4, alpha-fetoprotein.

## Stomach cancer laboratory findings

[edit | edit source]

* A complete blood cell count shows anemia of chronic disease.

* Liver function tests may be disturbed in patients with liver metastasis.

* Carcinoembryonic antigen (CEA) is elevated in 50% of patients. A drop in an elevated level of CEA means response to preoperative therapy but it is not sensitive or specific.

* Glycoprotein CA 125 antigen may be elevated.[1]
* Carbohydrate antigen 19-9 (CA 19-9) is elevated.[2]
* Cancer antigen 72-4 (CA72-4) may be elevated.[3]
* Alpha-fetoprotein (AFP) may be elevated.[4]

## References

[edit | edit source]

1. ↑ Luo T, Chen W, Wang L, Zhao H (2016). "CA125 is a potential biomarker to predict surgically incurable gastric and cardia cancer: A retrospective study". Medicine (Baltimore). 95 (51): e5297. doi:10.1097/MD.0000000000005297. PMC 5181804. PMID 28002320.CS1 maint: Multiple names: authors list (link)
2. ↑ Ucar E, Semerci E, Ustun H, Yetim T, Huzmeli C, Gullu M (2008). "Prognostic value of preoperative CEA, CA 19-9, CA 72-4, and AFP levels in gastric cancer". Adv Ther. 25 (10): 1075–84. doi:10.1007/s12325-008-0100-4. PMID 18821070.CS1 maint: Multiple names: authors list (link)
3. ↑ Guadagni F, Roselli M, Cosimelli M, Ferroni P, Spila A, Cavaliere F; et al. (1995). "CA 72-4 serum marker--a new tool in the management of carcinoma patients". Cancer Invest. 13 (2): 227–38. PMID 7874576.CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
4. ↑ Kono K, Amemiya H, Sekikawa T, Iizuka H, Takahashi A, Fujii H; et al. (2002). "Clinicopathologic features of gastric cancers producing alpha-fetoprotein". Dig Surg. 19 (5): 359–65, discussion 365. doi:10.1159/000065838. PMID 12435906.CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)

Template:WH Template:WS